logo
logo
Sign in

Protein Engineering Market Having a Great Future Ahead

avatar
Nilkanth Rathod
Protein Engineering Market Having a Great Future Ahead

The growth of this market is majorly driven by factors such as the increasing investments in synthetic biology and the growing focus on protein-based drug development by pharmaceutical and biotechnology companies. 

The large share of this segment can be attributed to the increasing demand for monoclonal antibodies for the treatment of cancer, neurological diseases, and infectious diseases.

Rational protein design is the largest technology segment in the protein engineering market

Based on technology, the neering market is segmented into rational and irrational protein design. The rational protein design segment accounted for the largest share of the market in 2019. The large share of this segment can be attributed to the increasing use and continuous upgrades of bioinformatics platforms and software for protein analysis. 

Biopharmaceutical companies were the largest end-users of protein engineering products and services in 2019

Based on end-user, the market is segmented into biopharmaceutical companies, contract research organizations, and academic research institutes. The biopharmaceutical companies segment accounted for the largest share of the market in 2019. 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=898

 Factors such as the presence of well-established CROs, rising R&D expenditure, and the availability of the latest techniques and instruments for drug discovery research are responsible for the large share of the North American market. However, the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. This can majorly be attributed to the advancements in genomics and proteomics research and government initiatives and funding for protein-based drug research in several Asia Pacific countries. 

Key Market Players

The major companies operating in the protein engineering market include Thermo Fisher Scientific (US), Danaher Corporation (US), Agilent Technologies (US), and Bio-Rad Laboratories (US). 

Recent Developments:

  • In 2019, Creative Biolabs (US) launched the cd25 monoclonal antibody.
  • In 2019, Waters Corporation (US) launched Vanguard FIT Cartridge Technology.
  • In 2019, Agilent Technologies (US) acquired BioTek Instruments (US), which helped the company to expand its expertise in cell analysis and establish its position in the immuno-oncology and immunotherapy markets.
collect
0
avatar
Nilkanth Rathod
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more